Literature DB >> 30737319

Reply to Koh: Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent.

Nicholas J H Warren1, Alan Eastman2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30737319      PMCID： PMC6369300          DOI： 10.1074/jbc.RL119.007419

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


× No keyword cloud information.
  5 in total

1.  Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Authors:  Siang-Boon Koh; Yann Wallez; Charles R Dunlop; Sandra Bernaldo de Quirós Fernández; Tashinga E Bapiro; Frances M Richards; Duncan I Jodrell
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

2.  Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.

Authors:  Nicholas J H Warren; Alan Eastman
Journal:  J Biol Chem       Date:  2018-12-20       Impact factor: 5.157

3.  Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent.

Authors:  Siang-Boon Koh
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157

4.  Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.

Authors:  Ryan Montano; Ruth Thompson; Injae Chung; Huagang Hou; Nadeem Khan; Alan Eastman
Journal:  BMC Cancer       Date:  2013-12-21       Impact factor: 4.430

5.  Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.

Authors:  Ryan Montano; Nadeem Khan; Huagang Hou; John Seigne; Marc S Ernstoff; Lionel D Lewis; Alan Eastman
Journal:  Oncotarget       Date:  2017-06-28
  5 in total
  1 in total

1.  Diabetic Bone Marrow Cell Injection Accelerated Acute Pancreatitis Progression.

Authors:  Xiao-Min Luo; Cen Yan; Yue-Jie Zhang; Ling-Jia Meng; Guo-Tao Lu; Ji-Ming Yin; Ying-Mei Feng
Journal:  J Immunol Res       Date:  2021-08-21       Impact factor: 4.818
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.